BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-591@pharmaconomics
DTSTAMP:20260707T003415Z
DTSTART;VALUE=DATE:20260930
DTEND;VALUE=DATE:20261001
SUMMARY:IMMX Phase 2 — NXC-201 (estimated date)
DESCRIPTION:Phase 2 trial results for NXC-201 in its lead indication are due ~ Sep 30\, 2026. A clean hit validates the program\; a miss can gap the stock down hard.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1873835/000149315226013663/form8-k.htm\n\nTrack it: https://pharmaconomics.com/e/591
URL:https://pharmaconomics.com/e/591
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:IMMX catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR